Orserdu combined with Afinitor or Verzenio shows favorable tolerability and progression-free survival in ER-positive, ...

Please provide your email address to receive an email when new articles are posted on . Pembrolizumab plus axitinib continued to exhibit superior efficacy to sunitinib as first-line therapy for ...

BOSTON - An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in ...

Please provide your email address to receive an email when new articles are posted on . Hepatocellular carcinoma accounts for approximately 90% of all primary liver cancer cases, according to Zhen-Wei ...

Bristol-Myers Squibb Company today announced five-year results from the Phase 3 CheckMate -067 clinical trial, which continues to demonstrate improved overall survival with the first-line combination ...

A new report outlines helpful strategies for pediatric patients with pulmonary arterial hypertension, although experts say more research is needed to catch up with advances in the field. Children with ...

HOUSTON - A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the ...

Researchers at the University of California, San Diego (UCSD) School of Medicine report that treating patients with personalized, combination therapies improved outcomes in patients with ...

Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy was safe and improved survival outcomes in a subset of ...

Derek van Amerongen, MD, MS: One of the important topics of discussion within a health plan, whenever we’re discussing treatment A versus treatment B, especially at the P&T discussions, is, what does ...

Shuo Ma, MD, '00 PhD, associate professor of Medicine in the Division of Hematology and Oncology, was co-first author of the clinical trial published in Blood. A combination therapy pairing a small ...

49% of patients treated with Opdivo plus Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free Data to be featured in an oral presentation during the 2021 American Society ...